tetano
Editor, Senior Moderator
Sci Rep
. 2023 Jun 1;13(1):8926.
doi: 10.1038/s41598-023-36070-y. Epigenomic landscape exhibits interferon signaling suppression in the patient of myocarditis after BNT162b2 vaccination
Hyeonhui Kim[SUP] #[/SUP][SUP] 1 2 [/SUP], Hyo-Suk Ahn[SUP] #[/SUP][SUP] 3 4 [/SUP], Nahee Hwang[SUP] 1 5 [/SUP], Yune Huh[SUP] 6 [/SUP], Seonghyeon Bu[SUP] 3 4 [/SUP], Kyung Jin Seo[SUP] 7 [/SUP], Se Hwan Kwon[SUP] 8 [/SUP], Hae-Kyung Lee[SUP] 2 [/SUP], Jae-Woo Kim[SUP] 5 [/SUP], Bo Kyung Yoon[SUP] 9 [/SUP], Sungsoon Fang[SUP] 10 11 [/SUP]
Affiliations
After the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, a novel mRNA vaccine (BNT162b2) was developed at an unprecedented speed. Although most countries have achieved widespread immunity from vaccines and infections, yet people, even who have recovered from SARS-CoV-2 infection, are recommended to receive vaccination due to their effectiveness in lowering the risk of recurrent infection. However, the BNT162b2 vaccine has been reported to increase the risk of myocarditis. To our knowledge, for the first time in this study, we tracked changes in the chromatin dynamics of peripheral blood mononuclear cells (PBMCs) in the patient who underwent myocarditis after BNT162b2 vaccination. A longitudinal study of chromatin accessibility using concurrent analysis of single-cell assays for transposase-accessible chromatin with sequencing and single-cell RNA sequencing showed downregulation of interferon signaling and upregulated RUNX2/3 activity in PBMCs. Considering BNT162b2 vaccination increases the level of interferon-α/γ in serum, our data highlight the immune responses different from the conventional responses to the vaccination, which is possibly the key to understanding the side effects of BNT162b2 vaccination.
. 2023 Jun 1;13(1):8926.
doi: 10.1038/s41598-023-36070-y. Epigenomic landscape exhibits interferon signaling suppression in the patient of myocarditis after BNT162b2 vaccination
Hyeonhui Kim[SUP] #[/SUP][SUP] 1 2 [/SUP], Hyo-Suk Ahn[SUP] #[/SUP][SUP] 3 4 [/SUP], Nahee Hwang[SUP] 1 5 [/SUP], Yune Huh[SUP] 6 [/SUP], Seonghyeon Bu[SUP] 3 4 [/SUP], Kyung Jin Seo[SUP] 7 [/SUP], Se Hwan Kwon[SUP] 8 [/SUP], Hae-Kyung Lee[SUP] 2 [/SUP], Jae-Woo Kim[SUP] 5 [/SUP], Bo Kyung Yoon[SUP] 9 [/SUP], Sungsoon Fang[SUP] 10 11 [/SUP]
Affiliations
- PMID: 37264110
- DOI: 10.1038/s41598-023-36070-y
After the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, a novel mRNA vaccine (BNT162b2) was developed at an unprecedented speed. Although most countries have achieved widespread immunity from vaccines and infections, yet people, even who have recovered from SARS-CoV-2 infection, are recommended to receive vaccination due to their effectiveness in lowering the risk of recurrent infection. However, the BNT162b2 vaccine has been reported to increase the risk of myocarditis. To our knowledge, for the first time in this study, we tracked changes in the chromatin dynamics of peripheral blood mononuclear cells (PBMCs) in the patient who underwent myocarditis after BNT162b2 vaccination. A longitudinal study of chromatin accessibility using concurrent analysis of single-cell assays for transposase-accessible chromatin with sequencing and single-cell RNA sequencing showed downregulation of interferon signaling and upregulated RUNX2/3 activity in PBMCs. Considering BNT162b2 vaccination increases the level of interferon-α/γ in serum, our data highlight the immune responses different from the conventional responses to the vaccination, which is possibly the key to understanding the side effects of BNT162b2 vaccination.